Discover more
than you think
Developing innovative treatments in immuno-oncology, CNS and rare diseases
Proprietary
programs
We are advancing multiple first-in-class and best-in class programs.
| Name | Discovery | Candidate | Preclinical | Clinical | Partner |
|---|---|---|---|---|---|
| Adenosine A2AR antagonist |
Preclinical
|
||||
| Multi-target collaboration for CNS |
Discovery
|
||||
| Multi-target collaboration for rare diseases |
Discovery
|
||||
Asset-centric
companies
Giving each program the best path forward
We create asset-centric vehicles for the development of our internal pipeline of preclinical candidates or to accelerate breakthrough innovations coming from academia. These asset-centric companies benefit from dedicated teams and targeted investments for a focused development.
-
Discover more
First-in-class CXCR4 agonist to control auto-immune diseases
-
Discover more
Sema3A fusion protein for immuno-oncology
-
Discover more
First-in-class mGluR3 PAM for Parkinson’s disease
-
Discover more
Transmembrane peptide-based platform
-
Discover more
EXITED - acquired by Lundbeck 2018
-
Discover more
EXITED - out-licensed to Merck 2017
Discovery
engine
We build a strong pipeline using our drug discovery platforms to tackle brand new targets, challenging or orphan GPCRs considered intractable targets.
